Year All202320222021202020192018201720162015 Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma August 30, 2021 Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021 August 12, 2021 Poseida Therapeutics Appoints Cynthia Collins to Board of Directors July 26, 2021 Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders June 2, 2021 Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021 May 11, 2021 Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting May 11, 2021 Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board May 6, 2021 Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care Conference May 5, 2021 Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting April 27, 2021 Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences April 8, 2021
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma August 30, 2021
Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021 August 12, 2021
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021 May 11, 2021
Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting May 11, 2021
Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board May 6, 2021
Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting April 27, 2021
